BGB324
In human trialsMeasured in people, not heightBy mouthSmall moleculeAlso bemcentinib
An experimental cancer drug that blocks a receptor holding bone-building cells back from maturing.
A selective small-molecule AXL inhibitor from BerGenBio, taken into oncology trials. No regulatory approval, and no skeletal or paediatric indication.
Risks. It cut the white blood cell count of the treated mice by about two thirds, and the receptor it blocks also runs immune and blood vessel jobs.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.